Related Experiment Video

Updated: Aug 30, 2026

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine
05:36

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine

Published on: January 30, 2020

Risk stratification and management of sudden cardiac death: a new paradigm

Nabil El-Sherif1, Gioia Turitto

  • 1Cardiology Division, Department of Medicine, State University of New York, Downstate Medical Center, and New York Harbor Health Care Center, Brooklyn, New York, USA. nelsherif@aol.com

Journal of Cardiovascular Electrophysiology
|October 3, 2003
PubMed

Insights

Sudden cardiac death (SCD) management is evolving. New markers beyond traditional tools are identifying high-risk patients with atherosclerotic coronary artery disease for better prevention strategies.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Cardiology
  • Biomarkers and Diagnostics

Background:

  • Sudden cardiac death (SCD) management is shifting towards more personalized risk assessment.
  • Conventional risk stratification tools for atherosclerotic coronary artery disease (CAD) have limitations in identifying all high-risk individuals.
  • Emerging understanding of pathophysiologic processes like myocardial remodeling and heart failure transition is crucial.

Purpose of the Study:

  • To explore novel risk stratification markers for SCD in patients with atherosclerotic coronary artery disease.
  • To improve the identification of individuals at high risk for SCD versus non-fatal ischemic events.
  • To enhance the management and prevention strategies for SCD in the general population.

Main Methods:

  • Evaluation of new markers including plaque vulnerability, thrombogenesis, genetic factors, and protein alterations.
  • Assessment of pathophysiologic processes such as post-myocardial infarction remodeling and heart failure.
  • Consideration of advanced technologies like microchips and proteomics for mass screening of risk factors.

Main Results:

  • New markers may offer superior segregation of patients at high risk for SCD compared to conventional methods.
  • Understanding of specific pathophysiologies (e.g., diabetes, prediabetes) improves risk stratification and management.
  • Technological advancements promise cost-effective mass screening for multiple SCD risk factors.

Conclusions:

  • A paradigm shift in SCD management necessitates incorporating novel risk stratification tools.
  • Integrated understanding of plaque, genetic, and pathophysiologic factors is key to personalized SCD risk assessment.
  • Future strategies aim for broad application of novel risk modification and prevention methods for SCD.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...